Your browser doesn't support javascript.
loading
["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy]. / "Time is brain" bei der schubförmigen Multiplen Sklerose. Aktuelle Behandlungskonzepte in der Immuntherapie.
Linker, R; Kallmann, B-A; Kleinschnitz, C; Rieckmann, P; Mäurer, M; Schwab, S.
Afiliación
  • Linker R; Neurologische Klinik, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Deutschland. ralf.linker@uk-erlangen.de.
  • Kallmann BA; Neurologische Praxis und multiple sklerose zentrum Bamberg, Bamberg, Deutschland.
  • Kleinschnitz C; Neurologische Klinik und Poliklinik des Universitätsklinikums Würzburg, Würzburg, Deutschland.
  • Rieckmann P; Neurologische Klinik, Klinikum am Bruderwald der Sozialstiftung Bamberg , Bamberg, Deutschland.
  • Mäurer M; Neurologie, Caritas-Krankenhaus Bad Mergentheim gGmbH, Bad Mergentheim, Deutschland.
  • Schwab S; Neurologische Klinik, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Deutschland.
Nervenarzt ; 86(12): 1528-37, 2015 Dec.
Article en De | MEDLINE | ID: mdl-26556094
ABSTRACT

BACKGROUND:

Despite highly divergent time scales of disease evolution in multiple sclerosis (MS) and ischemic stroke, clear analogies are apparent that may point the way to optimization of MS treatment. Inflammatory disease activity and neurodegeneration may induce potentially irreversible damage to central nervous system structures and thus lead to permanent disability. For the treatment of MS early detection of disease activity and early immunotherapy or treatment optimization are pivotal determinants of long-term outcomes. Such therapeutic concepts may be described with the catchy phrase "time is brain" as coined for the acute thrombolytic treatment of ischemic stroke. RESULTS AND

DISCUSSION:

For MS a "time is brain" concept would comprise an early initiation of first line therapy as well as sensitive and structured monitoring of disease activity under therapy in conjunction with a low threshold for timely treatment optimization to achieve sustained freedom from measurable disease activity. This approach may substantially improve the long-term outcome in patients who show insufficient response to platform therapies. The intersectorial collaboration in regional MS care networks involving office-based neurologists and specialized MS centers may facilitate the timely use of highly active therapies with their specific benefit-risk profiles thus supporting sustained stabilization of patient quality of life.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Inmunosupresores / Inmunoterapia Tipo de estudio: Diagnostic_studies / Qualitative_research / Screening_studies Aspecto: Patient_preference Límite: Humans Idioma: De Revista: Nervenarzt Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Inmunosupresores / Inmunoterapia Tipo de estudio: Diagnostic_studies / Qualitative_research / Screening_studies Aspecto: Patient_preference Límite: Humans Idioma: De Revista: Nervenarzt Año: 2015 Tipo del documento: Article